HC Wainwright Has Bearish Estimate for INO Q2 Earnings

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – HC Wainwright decreased their Q2 2025 earnings estimates for Inovio Pharmaceuticals in a research note issued to investors on Wednesday, May 14th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will earn ($0.69) per share for the quarter, down from their previous forecast of ($0.55). HC Wainwright has a “Neutral” rating and a $3.00 price target on the stock. The consensus estimate for Inovio Pharmaceuticals’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.49) EPS and FY2025 earnings at ($2.22) EPS.

Several other research firms have also recently commented on INO. Oppenheimer cut their price objective on shares of Inovio Pharmaceuticals from $15.00 to $13.00 and set an “outperform” rating on the stock in a research report on Wednesday. Royal Bank of Canada restated a “sector perform” rating and issued a $5.00 price target on shares of Inovio Pharmaceuticals in a report on Wednesday. Finally, StockNews.com cut Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $9.75.

Inovio Pharmaceuticals Trading Up 3.7%

NASDAQ:INO opened at $1.95 on Friday. The stock has a market cap of $71.51 million, a price-to-earnings ratio of -0.49 and a beta of 1.40. The stock has a 50-day moving average price of $1.80 and a two-hundred day moving average price of $2.53. Inovio Pharmaceuticals has a 1 year low of $1.42 and a 1 year high of $13.44.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.23. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.01 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of INO. AQR Capital Management LLC acquired a new stake in shares of Inovio Pharmaceuticals in the 1st quarter valued at $120,000. Nomura Holdings Inc. acquired a new stake in shares of Inovio Pharmaceuticals in the 1st quarter valued at approximately $28,000. Freedom Investment Management Inc. acquired a new stake in shares of Inovio Pharmaceuticals in the 1st quarter valued at approximately $31,000. Nuveen LLC bought a new stake in shares of Inovio Pharmaceuticals during the 1st quarter valued at approximately $168,000. Finally, Charles Schwab Investment Management Inc. increased its position in Inovio Pharmaceuticals by 38.6% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 98,495 shares of the biopharmaceutical company’s stock worth $161,000 after purchasing an additional 27,429 shares in the last quarter. Institutional investors and hedge funds own 26.79% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.